Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)

NCT04905693 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT04905693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04905693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)
Lead sponsor
United Therapeutics
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
September 6, 2022
Completion date
December 31, 2029
Enrollment
1,850 (estimated)
Sites
190

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis, interstitial lung disease, progressive pulmonary fibrosis